Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics (Nasdaq: ATRA) has announced six poster presentations at the upcoming Transplantation & Cellular Therapy (TCT) Meeting, occurring virtually from February 8-12, 2021. The presentations will focus on Atara's innovative allogeneic EBV T-cell platform, highlighting the mechanism of action of tabelecleucel (tab-cel®) and an assay for non-engineered T-cell therapies. Key posters include studies on tabelecleucel's clinical efficacy and the development of a new CAR-T therapy, ATA3219, without gene editing.
Atara Biotherapeutics (Nasdaq: ATRA) revealed its strategic priorities and progress at the upcoming J.P. Morgan Healthcare Conference on January 13, 2021. CEO Pascal Touchon emphasized significant advancements in 2020, particularly for its lead candidate tab-cel® for EBV-positive post-transplant lymphoproliferative disease. Key milestones include the completion of the BLA rolling submission and anticipated approvals in the U.S. and EU in 2022. Additionally, Atara plans to provide updates on ATA188 for progressive MS and CAR T programs throughout the year.
Atara Biotherapeutics (Nasdaq: ATRA) announced that CEO Pascal Touchon will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 1:30 PM PST/4:30 PM EST. This event will showcase Atara's advancements in T-cell immunotherapy, particularly its allogeneic EBV T-cell platform aimed at treating serious diseases like solid tumors and autoimmune disorders. A live audio webcast will be available on atarabio.com, with a recorded version accessible for 30 days post-event.
Atara Biotherapeutics (Nasdaq: ATRA) has not yet initiated the Biologics License Application (BLA) for tab-cel® (tabelecleucel), under Phase 3 development for EBV-positive post-transplant lymphoproliferative disease. The Company awaits a procedural decision from the FDA regarding historical data presentation in the BLA. Despite the delay, Atara remains on track to complete the BLA filing in Q3 2021, with an objective response rate of 50% reported in the pivotal study. Ongoing discussions with the FDA are described as constructive.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced a public offering of 5,102,041 shares at $24.50 each and pre-funded warrants for 2,040,816 shares at $24.4999, totaling approximately $175 million in gross proceeds. The offering is set to close on December 11, 2020, pending customary conditions. Citigroup, Evercore ISI, and Mizuho Securities serve as joint book-running managers, with an option for underwriters to purchase an additional 1,071,428 shares. The offering is conducted under a previously filed registration statement with the SEC.
Atara Biotherapeutics (Nasdaq: ATRA) has initiated a public offering of $150 million in common stock, with a potential additional $22.5 million from underwriters. The offering is subject to market conditions, and there are no guarantees regarding its completion or terms. The shares will be sold by Atara Biotherapeutics, leveraging a previously filed shelf registration statement with the SEC. Citigroup, Evercore ISI, and Mizuho Securities are acting as joint book-running managers for this offering.
Atara Biotherapeutics (Nasdaq: ATRA) announced the first preclinical evaluation of ATA3219, a novel off-the-shelf CAR T-cell therapy targeting CD19, and data from its Phase II study of tab-cel® for EBV-driven diseases. The results showcased ATA3219's potent antitumor activity and safety in preclinical models. Atara plans to submit an IND for ATA3219 in 2021 following a successful FDA meeting. Additionally, tab-cel® demonstrated high response rates in patients with life-threatening EBV viremia, with an overall survival rate of 100% at one year.
Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) have entered a global license agreement for mesothelin-directed CAR T-cell therapies targeting solid tumors. This collaboration involves the development candidate ATA3271 and an autologous version, ATA2271. Atara will oversee IND-enabling studies while Bayer manages the IND submission and clinical development. Atara receives an upfront payment of $60 million and can earn up to $610 million in milestones plus royalties on net sales. This partnership aims to enhance the development of off-the-shelf CAR T-cell therapies for challenging cancer types.
Atara Biotherapeutics, a leader in T-cell immunotherapy, has announced participation in two upcoming virtual conferences. The Stifel 2020 Virtual Healthcare Conference is set for November 18, 2020, featuring a fireside chat with CEO Pascal Touchon. The Evercore ISI 3rd Annual Virtual HealthCONx Conference will take place on December 2, 2020, with chats including Pascal Touchon and Jakob Dupont, Global Head of Research and Development. Both events will be accessible via live webcasts on the company's website, with archived replays available for 14 days.
Atara Biotherapeutics (Nasdaq: ATRA) announced promising 15-month safety and efficacy data for ATA188, a treatment for progressive multiple sclerosis (MS), presented at the European Charcot Foundation's 28th Annual Meeting. In a Phase 1a study, 50% of patients showed sustained disability improvement, indicating a potential treatment effect. Atara plans to enhance its investment in the ATA188 program, expanding the randomized controlled trial to at least 64 patients and focusing on disability improvement as the primary endpoint. This treatment addresses a significant unmet need in MS.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
